Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin for Impulse Control Disorders in Parkinson's Disease
2016-001229-15Phase 2Completed
- Sponsor
- Strasbourg University Hospital
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pimavanserin in impulse control disorder (ICD), sponsored by Strasbourg University Hospital. Primary endpoint: Change in ICD severity. Started Jul 2019; status: completed.
02
Drugs
pimavanserin
03
Conditions
impulse control disorder (ICD)
Beyond the preview
Go deeper on 2016-001229-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001229-15.